Artificial intelligence systems require consistent monitoring and staffing to put in place and to keep them working well.

Adding atezolizumab to adjuvant chemotherapy does not improve outcomes in patients with stage II-III TNBC, phase 3 data suggest.

Tislelizumab plus low-dose nab-paclitaxel “demonstrated enduring efficacy while maintaining a manageable safety profile,” according to researchers.

Some patients who had disease progression after stopping larotrectinib achieved a response after resuming larotrectinib.

Provider prioritization of relationship-building alongside explanations could foster trust and facilitate open information exchange, supporting informed decisions,” researchers wrote.

Men with prostate cancer are living longer than ever, and our goal is to reduce the risk of late toxicities, such as difficulty urinating or rectal bleeding, that can impact a patient’s quality of ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

Antihistamine use may improve oncologic and survival outcomes in patients receiving second-line atezolizumab for advanced or metastatic urothelial carcinoma, according to research published in ...

In a survey, less than half of cancer patients and their family members said they were willing to participate in a clinical trial, and about a third of respondents said they had a positive perception ...

Researchers found that, in patients with stage III NSCLC, treatment with cCRT and an ICI was safe, but treatment with cCRT and 2 ICIs led to “excessive mortality.” ...

Burnout in US oncologists has increased over the past 10 years, according to results of 2 surveys. 1 Researchers compared results of a 2023 survey of 328 oncologists to results of a 2013 survey of ...

The improvement in the well-being of fellows over the past decade likely stems from intentional changes to training programs,” researchers wrote.